Trimazosin

Trimazosin is a sympatholytic alpha-1 blocker.[1][2]

Trimazosin
Clinical data
ATC code
Identifiers
IUPAC name
  • (2-Hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.047.924
Chemical and physical data
FormulaC20H29N5O6
Molar mass435.481 g·mol−1
3D model (JSmol)
SMILES
  • O=C(OCC(O)(C)C)N3CCN(c1nc(N)c2c(n1)c(OC)c(OC)c(OC)c2)CC3
InChI
  • InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23) N
  • Key:YNZXWQJZEDLQEG-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

References
  1. van Kalken CK, van der Meulen J, Oe PL, Vriesendorp R, Donker AJ (1986). "Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension". Eur. J. Clin. Pharmacol. 31 (1): 63–8. doi:10.1007/BF00870988. PMID 3780829. S2CID 19123951.
  2. U.S. Patent 3,669,968



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.